$2.70-0.07 (-2.53%)
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
Equillium, Inc. in the Healthcare sector is trading at $2.70. Wall Street consensus targets $7.12 (8 analysts), implying a +163.9% move over the next 12 months. The stock is currently 22% below its 52-week high of $3.45, remaining 62.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinica...
Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflammatory disease biology. The presentation, titled “Insights to
Equillium, Inc. (NASDAQ:EQ) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 13, Roth Capital analyst Adam Walsh initiated coverage of Equillium, Inc. (NASDAQ:EQ), assigning a Buy rating and a price target of $12. The firm’s assigned price target suggests a compelling 458% upside from the current levels. The […]
Executives from Equillium (NASDAQ:EQ) outlined the scientific rationale and near-term development plans for its lead program, EQ504, during a recent fireside chat focused on immunology and inflammatory bowel disease (IBD). Positioning EQ504 in ulcerative colitis Company representatives described ul
The latest investor updates on stocks that are trending on Tuesday
Gibo Holdings Ltd. 239,477,124 0.049